Actively Recruiting
Observational Study of Real-World Use and Safety of Xanomeline and Trospium Chloride KarXT in Adults with Schizophrenia
Led by Bristol-Myers Squibb · Updated on 2026-11-02
1500
Participants Needed
68
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing adults diagnosed with schizophrenia in the United States who have started treatment with xanomeline and trospium chloride KarXT. The study aims to describe real-world treatment patterns, effectiveness, and adverse events related to KarXT use in routine clinical care. Participants are those who have initiated KarXT treatment within 16 weeks with plans to discontinue prior antipsychotic treatments or are on stable antipsychotic regimens planning to switch to KarXT. The study follows these participants for up to 20 weeks to record treatment titration, switches, and continuation patterns. Concomitant psychiatric medications may continue at stable doses during the study. During the study, researchers collect data on adverse events, weight changes, clinical global improvement scores, schizophrenia-related relapses, treatment discontinuation reasons, and use of antiemetic treatments for gastrointestinal symptoms. Baseline information includes demographics, family history, diagnosis duration, and previous treatments. This observational study supports understanding KarXT treatment in real-world settings up to 20 weeks after initiation.
CONDITIONS
Brief Title
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here